Marlborough, MA's Theracos raised $25 million to support its work on a safer version of a common treatment for Type 2 diabetes. As MedCity News reports, the company is at work on a drug that blocks a protein called SGLT2, diverting excess blood sugars out through the urine to harmonize patients' glucose levels. AstraZeneca ($AZN), Johnson & Johnson ($JNJ) and others already market SGLT2 therapies, but each has been marked by risks of urinary and genital infections. Theracos believes its agent, bexagliflozin, could provide a safer alternative with similar efficacy. More